Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2014 1
2015 1
2016 3
2017 3
2018 2
2019 9
2020 8
2021 11
2022 13
2023 20
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Alsoud D, Moes DJAR, Wang Z, Soenen R, Layegh Z, Barclay M, Mizuno T, Minichmayr IK, Keizer RJ, Wicha SG, Wolbink G, Lambert J, Vermeire S, de Vries A, Papamichael K, Padullés-Zamora N, Dreesen E. Alsoud D, et al. Among authors: moes djar. Ther Drug Monit. 2024 Apr 17. doi: 10.1097/FTD.0000000000001204. Online ahead of print. Ther Drug Monit. 2024. PMID: 38648666
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib.
Yin A, Veerman GDM, van Hasselt JGC, Steendam CMJ, Dubbink HJ, Guchelaar HJ, Friberg LE, Dingemans AC, Mathijssen RHJ, Moes DJAR. Yin A, et al. Among authors: moes djar. CPT Pharmacometrics Syst Pharmacol. 2024 Apr;13(4):612-623. doi: 10.1002/psp4.13105. Epub 2024 Feb 20. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38375997 Free PMC article.
Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial.
Stoelinga AEC, Tushuizen ME, van den Hout WB, Girondo MDMR, de Vries ES, Levens AD, Moes DAR, Gevers TJG, van der Meer S, Brouwer HT, de Jonge HJM, de Boer YS, Beuers UHW, van der Meer AJ, van den Berg AP, Guichelaar MMJ, Drenth JPH, van Hoek B; Dutch Autoimmune Hepatitis Group. Stoelinga AEC, et al. Among authors: moes dar. Trials. 2024 Jan 17;25(1):61. doi: 10.1186/s13063-023-07832-w. Trials. 2024. PMID: 38233878 Free PMC article.
Voclosporin and the Antiviral Effect Against SARS-CoV-2 in Immunocompromised Kidney Patients.
Arends EJ, Meziyerh S, Moes DJAR, Kamerling SWA, van der Kooy S, Ogando NS, Snijder EJ, van Hemert M, Visser LG, Feltkamp MCW, Claas ECJ, Rabelink TJ, van Kooten C, de Vries APJ, Teng YKO. Arends EJ, et al. Among authors: moes djar. Kidney Int Rep. 2023 Sep 7;8(12):2654-2664. doi: 10.1016/j.ekir.2023.09.003. eCollection 2023 Dec. Kidney Int Rep. 2023. PMID: 38106593 Free PMC article.
CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients.
van Eerden RAG, IJzerman NS, van Meekeren M, Oomen-de Hoop E, Guchelaar NAD, Visser AMW, Matic M, van Schaik RHN, de Bruijn P, Moes DAR, Jobse PA, Gelderblom H, Huitema ADR, Steeghs N, Mathijssen RHJ, Koolen SLW; Dutch Pharmacology Oncology Group. van Eerden RAG, et al. Among authors: moes dar. Clin Pharmacokinet. 2023 Aug;62(8):1129-1139. doi: 10.1007/s40262-023-01260-4. Epub 2023 Jun 13. Clin Pharmacokinet. 2023. PMID: 37310647 Free PMC article.
Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study.
Achini-Gutzwiller FR, Schilham MW, von Asmuth EGJ, Jansen-Hoogendijk AM, Jol-van der Zijde CM, van Tol MJD, Bredius RGM, Güngör T, Lankester AC, Moes DJAR. Achini-Gutzwiller FR, et al. Among authors: moes djar. Blood Adv. 2023 Aug 22;7(16):4462-4474. doi: 10.1182/bloodadvances.2022009051. Blood Adv. 2023. PMID: 37285798 Free PMC article.
67 results